Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency

NCT05877560 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation shorten the treatment time of office-based vergence/accommodative therapy for convergence insufficiency? 2. Is non-invasive brain stimulation alone just as effective as office-based vergence/accommodative therapy in treating convergence insufficiency? The investigators hypothesize that non-invasive brain stimulation will shorten the treatment time from 12 weeks to 8 weeks of office-based vergence/accommodative therapy and that non-invasive brain stimulation alone would be equally effective as office-based vergence/accommodative therapy in improving symptomatic convergence insufficiency. Participants will be randomized into one of three treatment groups: 1. Non-invasive brain stimulation with office-based vergence/accommodative therapy. 2. Sham stimulation with office-based vergence/accommodative therapy. 3. Non-invasive brain stimulation only. Researchers will compare baseline measurements of near point of convergence (NPC) and positive fusional vergence (PFV) to post-treatment measurements for each group.

Conditions Studied

Interventions

  • DEVICE Anodal-Transcranial Direct Current Stimulation
  • BEHAVIORAL Office-Based Vergence/Accommodative Therapy
  • DEVICE Sham Transcranial Direct Current Stimulation

Study Locations (1)

Illinois

  • Midwestern University Eye Institute — Downers Grove

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-03-01
Est. Completion 2028-12-31
Phase NA

Sponsor

Midwestern University

37 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05877560

The ClinicalTrials.gov registry entry for NCT05877560 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwestern University, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Convergence Insufficiency appearing as the primary indexed condition, and to 3 interventions — of which Anodal-Transcranial Direct Current Stimulation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05877560 reports 1 study location spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05877560 about?

NCT05877560 is a clinical study titled "Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency". The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation short...

What is the current status of trial NCT05877560?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-03-01. Estimated completion is 2028-12-31.

What conditions does trial NCT05877560 study?

This clinical trial studies the following conditions: Convergence Insufficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05877560?

The interventions under investigation include: Anodal-Transcranial Direct Current Stimulation (DEVICE), Office-Based Vergence/Accommodative Therapy (BEHAVIORAL), Sham Transcranial Direct Current Stimulation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05877560?

This trial is sponsored by Midwestern University, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05877560 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial